Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Antacid manufacturers stepped up their advertising efforts, introduced new products, and developed countless extensions for existing brands. At the same time, a new type of medication for treating ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

The result helped Q2 revenue increase by 7% over the same period. Merck has a broader product portfolio with more than 52 drugs covering categories like vaccines, hospital acute care, cardiology ...

When a pharmaceutical company such as Merck has an extremely successful product such as Keytruda, it can be both a blessing and a curse. Keytruda is a significant source of revenue growth for the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck has the potential to become a $3 billion product at peak for PAH, thanks to its to become the first drug for ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...